The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed
Globe Newswire (Wed, 18-Mar 11:30 AM ET)
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
Globe Newswire (Tue, 17-Mar 4:05 PM ET)
Longeveron's March 2026 Financial Results Date Signals Renewed Focus on Pipeline Progress
Market Chameleon (Fri, 13-Mar 6:30 AM ET)
Longeveron Secures $15 Million Upfront in Private Placement, Extending Cash Runway Into Late 2026
Market Chameleon (Thu, 12-Mar 7:46 AM ET)
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
Globe Newswire (Thu, 12-Mar 9:00 AM ET)
Longeveron Announces Closing of Private Placement of up to $30 Million
Globe Newswire (Wed, 11-Mar 4:05 PM ET)
Longeveron’s $30M Private Placement Extends Cash Runway Beyond Key Clinical Milestone
Market Chameleon (Tue, 10-Mar 5:54 AM ET)
Longeveron Announces Private Placement of up to $30 Million
Globe Newswire (Tue, 10-Mar 9:00 AM ET)
Globe Newswire (Wed, 25-Feb 11:05 AM ET)
Longeveron Appoints Stephen H. Willard as Chief Executive Officer
Globe Newswire (Fri, 13-Feb 4:30 PM ET)
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Longeveron - Class A trades on the NASDAQ stock market under the symbol LGVN.
As of April 1, 2026, LGVN stock price climbed to $1.12 with 1,481,502 million shares trading.
LGVN has a beta of 0.47, meaning it tends to be less sensitive to market movements. LGVN has a correlation of 0.00 to the broad based SPY ETF.
LGVN has a market cap of $32.79 million. This is considered a Sub-Micro Cap stock.
Last quarter Longeveron - Class A reported $365,000 in Revenue and -$.22 earnings per share. This beat revenue expectation by $258,802 and exceeded earnings estimates by $.16.
In the last 3 years, LGVN traded as high as $44.00 and as low as $.48.
The top ETF exchange traded funds that LGVN belongs to (by Net Assets): VTI, VXF.
LGVN has underperformed the market in the last year with a return of -27.7%, while SPY returned +18.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in LGVN shares. However, LGVN has outperformed the market in the last 3 month and 2 week periods, returning +121.3% and +16.7%, while SPY returned -3.6% and -2.1%, respectively. This indicates LGVN has been having a stronger performance recently.
LGVN support price is $.95 and resistance is $1.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LGVN shares will trade within this expected range on the day.
